In the multivariateanalysis considering factors such as age, stage and ALC-14,prior rituximab therapy has no impact on patient outcomehazard ratio??0.71 (95% CI: 0.33???1.47) Tables 2 and 3.The number of salvage regimens required before thetransplant did not appear to have an impact on the overalloutcome of patients in either group.Pre-transplant disease status and outcomeForty (56%) patients were